Recent Updates
Recently added Catalysts
FULC Positive Sentiment

Fulcrum Therapeutics to Participate in Upcoming September Conferences

Tuesday, August 27, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, has announced its participation in upcoming investor conferences, including the Wells Fargo Healthcare Conference on September 4, 2024, and the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024. This engagement reflects the company's ongoing efforts to connect with investors and promote its focus on developing therapies for genetically defined rare diseases.
Price reaction · baseline $9.74 (2024-08-26 close) · hit after-hours · clean, no other FULC news in the window
day 0 close
-9.1%
day 1
-8.9%
day 3 · peak
-12.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Fulcrum Therapeutics is actively participating in investor meetings, indicating engagement with stakeholders.
  • The company focuses on small molecules for rare genetic diseases, showcasing a commitment to addressing unmet medical needs.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+32%
120-day peak, hindsight
Typical move
15.6%
average across 6 past catalysts
Cash runway
~59 mo
Minimal dilution risk
Lead asset
Pociredir
Phase 2 · Sickle Cell Disease

Full Press Release Details

CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a series of investor meetings at the following conferences:
Wells Fargo Healthcare Conference
Wednesday, September 4, 2024
Morgan Stanley 22nd Annual Global Healthcare Conference
Friday, September 6, 2024
About Fulcrum Therapeutics

Frequently Asked Questions

What is Fulcrum Therapeutics focused on?

Fulcrum Therapeutics focuses on developing small molecules for patients with genetically defined rare diseases.

When is the Wells Fargo Healthcare Conference?

The Wells Fargo Healthcare Conference is on September 4, 2024.

What events will Fulcrum Therapeutics attend?

Fulcrum Therapeutics will participate in the Wells Fargo and Morgan Stanley conferences.

When is the Morgan Stanley Healthcare Conference?

The Morgan Stanley 22nd Annual Global Healthcare Conference is on September 6, 2024.

Who can be contacted for more information?

For inquiries, contact LifeSci Advisors at ccalabrese@lifesciadvisors.com.

ShareAdd on Google
Tags: FULC Viatris Investor Conferences Healthcare Fulcrum Therapeutics investor conferences rare diseases biopharmaceuticals
Last updated: Aug 27, 2024

Biotech snapshot

Cash runway
$319M liquidity · $5M/mo burn
~59 mo
Minimal dilution risk
Lead asset
PociredirPhase 2
Sickle Cell Disease →

Catalyst track record

+32%
best trade around FULC's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for FULC.

See every catalyst's timing & PoA →